Cencora Fiscal Q3 2026 Earnings: OneOncology Supports Margin Expansion

Cencora (NYSE: COR) reported fiscal Q3 2026 revenue of $84.8 billion for the quarter ended June 30, up 5.1% year over year, while GAAP diluted EPS increased to $3.94 from $3.52 and adjusted diluted EPS rose to $4.48 from $4.00. Profit grew faster than revenue as the OneOncology acquisition supported gross margin expansion and both reportable segments increased operating income, although acquisition expenses and higher interest costs provided offsets.

Core financial results

GAAP gross profit increased 24.1%, substantially faster than revenue, and gross margin expanded by 66 basis points. OneOncology was the principal margin driver, while a higher LIFO credit also helped GAAP results; increased sales of lower-margin GLP-1 products partly offset those benefits. Adjusted gross margin still rose by 61 basis points, indicating that the improvement was not limited to the LIFO effect.

GAAP operating expenses increased 21.9%, primarily because of costs associated with OneOncology. That increase was partly offset by a $102 million reduction in opioid liability following the dismissal of litigation. Below the operating line, net interest expense rose 72.0% as Cencora used senior notes and variable-rate term loans to finance part of the acquisition.

Adjusted operating income was $1.2 billion, up 17.0%, with adjusted operating margin increasing 15 basis points to 1.46%.

Business and segment performance

U.S. Healthcare Solutions remained the main source of revenue and operating profit growth. Higher unit volumes, specialty product sales to health systems and physician practices, and GLP-1 demand contributed to revenue, while OneOncology supported segment profit. These gains were partly offset by lower manufacturer prices for certain branded pharmaceuticals, the loss of an oncology customer in 2025, and reduced sales to a large mail-order customer.

International Healthcare Solutions benefited from European distribution and global specialty logistics. On a constant-currency basis, international revenue increased 6.1% and operating income rose 23.1%, slightly ahead of the reported growth rates.

Growth in Other came from Profarma and MWI Animal Health, partly offset by lower consulting sales following the April 2026 divestiture of U.S. Consulting Services. MWI Animal Health also benefited from lower depreciation after being classified as held for sale.

OneOncology lifted margins but also raised costs and interest

The February 2026 OneOncology acquisition created the quarter’s most important financial trade-off. It increased U.S. Healthcare Solutions gross profit and helped consolidated GAAP and adjusted gross margins expand, but it also drove higher operating expenses. Adjusted operating expenses rose 26.8%, compared with 23.2% growth in adjusted gross profit.

The financing impact was also visible. Net interest expense increased by $58.9 million to $140.7 million, reflecting acquisition-related debt and lower interest income. This helps explain why GAAP operating income grew 29.1% while attributable net income increased by a more moderate 11.1%.

Cencora repurchased $1 billion of shares during the quarter, completing the amount it had previously expected to repurchase by the end of calendar 2026. Diluted weighted-average shares declined 0.7% to 193.9 million, contributing to EPS growth modestly exceeding net income growth. The repurchase itself does not establish management’s view of the stock’s valuation.

Fiscal 2026 guidance

Cencora raised its fiscal 2026 adjusted diluted EPS range to $17.75-$17.95 from $17.70-$17.90, increasing both ends by $0.05. The company attributed the update to its full-year performance expectations and the share repurchases completed during the third quarter.

The following table summarizes the current adjusted outlook and the corresponding fiscal 2025 actual figures supplied by the company.

At the segment level, Cencora expects U.S. Healthcare Solutions adjusted operating income to grow 14.5% to 15.5%. International Healthcare Solutions and Other are expected to deliver approximately 9% and 10% adjusted operating income growth, respectively.

Recent insider transactions

The supplied insider data shows 51,516 shares purchased across 20 transactions during the last six months, compared with 5,095 shares sold in two transactions. That produced net purchases of 46,421 shares, equal to 0.60% of approximately 8.22 million total insider-held shares.

Among the records with clearly identified purchase prices and reported values, the latest open-market purchases were made by two directors.

These transactions are reported objectively and, on their own, do not establish insiders’ expectations for future business performance.

Risks investors should monitor

• Lower-margin product mix: GLP-1 sales are supporting revenue but carry lower gross margins. Continued mix shifts toward these products could limit margin expansion.
• Acquisition and financing costs: OneOncology is contributing to gross profit, but it is also increasing operating expenses and interest costs. The balance between those benefits and costs will remain important for net income growth.
• Pressure within U.S. distribution: Lower prices for certain branded drugs, the previous loss of an oncology customer, and reduced mail-order customer sales partially offset market and specialty-product growth this quarter.
• Higher full-year funding requirements: Fiscal 2026 guidance calls for approximately $490 million of net interest expense and $900 million of capital expenditures, both above fiscal 2025 levels, while adjusted free cash flow is expected to remain around $3.0 billion.

Summary

Cencora’s fiscal Q3 2026 results were defined by profit and margin growth that outpaced the 5.1% revenue increase. OneOncology strengthened U.S. Healthcare Solutions profitability, and international operations also contributed, but acquisition-related expenses, debt financing costs, lower-margin GLP-1 sales, and specific U.S. customer pressures remain important offsets. Investors should watch whether Cencora can sustain segment profit growth while meeting its raised adjusted EPS guidance and absorbing higher interest and capital spending.